FYI : More information about INVOKANA

Latest Data for Type 2 Diabetes Treatment INVOKANA™ (canagliflozin) to be Presented at American Diabetes Association Annual Meeting June 21-25th in Chicago.

INVOKANA is the first in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors to be approved in the United States. It is also the only oral, once-daily medication available in the United States offering improved glycemic control while also showing reduced body weight and systolic blood pressure in clinical trials.

INVOKANA™ acts on the kidneys, which make an important contribution to balancing blood glucose. As glucose is filtered from the blood into the kidneys, it is reabsorbed back into the bloodstream; SGLT2 is an important carrier responsible for this reabsorption, and appears to be elevated in people with type 2 diabetes, contributing to high levels of blood glucose. INVOKANA™ selectively inhibits SGLT2, promoting the loss of glucose in the urine and lowering blood glucose levels in adults with type 2 diabetes

***** Janssen Research & Development, a Johnson & Johnson Company